These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 7588401)

  • 1. Clinical investigation of 11 beta-hydroxysteroid dehydrogenase.
    Walker BR; Best R
    Endocr Res; 1995; 21(1-2):379-87. PubMed ID: 7588401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of 11 beta-hydroxysteroid dehydrogenase in the pathogenesis of hypertension.
    van Uum SH; Hermus AR; Smits P; Thien T; Lenders JW
    Cardiovasc Res; 1998 Apr; 38(1):16-24. PubMed ID: 9683905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apparent mineralocorticoid excess syndromes.
    Shimojo M; Stewart PM
    J Endocrinol Invest; 1995; 18(7):518-32. PubMed ID: 9221270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 11 beta-Hydroxysteroid dehydrogenases: key enzymes in determining tissue-specific glucocorticoid effects.
    Edwards CR; Benediktsson R; Lindsay RS; Seckl JR
    Steroids; 1996 Apr; 61(4):263-9. PubMed ID: 8733012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome.
    Walker BR; Campbell JC; Fraser R; Stewart PM; Edwards CR
    Clin Endocrinol (Oxf); 1992 Dec; 37(6):483-92. PubMed ID: 1337504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 11beta-hydroxysteroid dehydrogenase in cultured human vascular cells. Possible role in the development of hypertension.
    Hatakeyama H; Inaba S; Miyamori I
    Hypertension; 1999 May; 33(5):1179-84. PubMed ID: 10334808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess.
    White PC; Mune T; Agarwal AK
    Endocr Rev; 1997 Feb; 18(1):135-56. PubMed ID: 9034789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of hepatic and renal 11 beta-hydroxysteroid dehydrogenase in rats with liver cirrhosis.
    Escher G; Nawrocki A; Staub T; Vishwanath BS; Frey BM; Reichen J; Frey FJ
    Gastroenterology; 1998 Jan; 114(1):175-84. PubMed ID: 9428231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 11 beta-Hydroxysteroid dehydrogenase and its inhibitors in hypertensive pregnancy.
    Walker BR; Williamson PM; Brown MA; Honour JW; Edwards CR; Whitworth JA
    Hypertension; 1995 Apr; 25(4 Pt 1):626-30. PubMed ID: 7721407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [11 beta-Hydroxysteroid dehydrogenase (11-beta-OHSD): physiology and lack of action in pathology].
    Vantyghem MC; Hober C; Racadot A; Lefebvre J
    Ann Endocrinol (Paris); 1994; 55(6):271-7. PubMed ID: 7864584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organ-specific actions of 11 beta-hydroxysteroid dehydrogenase in humans: implications for the pathophysiology of hypertension.
    Walker BR
    Steroids; 1994 Feb; 59(2):84-9. PubMed ID: 8191553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.
    Stewart PM; Corrie JE; Shackleton CH; Edwards CR
    J Clin Invest; 1988 Jul; 82(1):340-9. PubMed ID: 3164727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle and heart: implications for cardiovascular responses to glucocorticoids.
    Walker BR; Yau JL; Brett LP; Seckl JR; Monder C; Williams BC; Edwards CR
    Endocrinology; 1991 Dec; 129(6):3305-12. PubMed ID: 1954906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Furosemide and 11beta-hydroxysteroid dehydrogenase activity, in man.
    Palermo M; Armanini D; Shackleton CH; Sorba G; Cossu M; Roitman E; Scaroni C; Delitala G
    Exp Clin Endocrinol Diabetes; 2002 Sep; 110(6):272-6. PubMed ID: 12373630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced 11beta-hydroxysteroid dehydrogenase activity in the remaining kidney following nephrectomy.
    Escher G; Vogt B; Beck T; Guntern D; Frey BM; Frey FJ
    Endocrinology; 1998 Apr; 139(4):1533-9. PubMed ID: 9528931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man.
    Walker BR; Connacher AA; Webb DJ; Edwards CR
    Clin Sci (Lond); 1992 Aug; 83(2):171-8. PubMed ID: 1327632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid hormones and hypertension: the cortisol-cortisone shuttle.
    Stewart PM; Whorwood CB; Walker BR
    Steroids; 1993 Dec; 58(12):614-20. PubMed ID: 8116018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cortisol-cortisone shuttle and the apparent specificity of glucocorticoid and mineralocorticoid receptors.
    Edwards CR; Stewart PM
    J Steroid Biochem Mol Biol; 1991 Nov; 39(5B):859-65. PubMed ID: 1659446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does kidney transplantation normalise cortisol metabolism in apparent mineralocorticoid excess syndrome?
    Palermo M; Delitala G; Sorba G; Cossu M; Satta R; Tedde R; Pala A; Shackleton CH
    J Endocrinol Invest; 2000; 23(7):457-62. PubMed ID: 11005270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension.
    Walker BR; Stewart PM; Shackleton CH; Padfield PL; Edwards CR
    Clin Endocrinol (Oxf); 1993 Aug; 39(2):221-7. PubMed ID: 8370136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.